Oral Antiplatelet Therapy for Secondary Prevention of Acute Coronary Syndrome.

In PLATO, the benefit of ticagrelor in the subgroup of patients with ACS and PAD was consistent with the overall trial results, but did not reach statistical significance [ 104 ].

also in 111,027 other papers

Similarly, outcomes from TRACER showed a trend toward a reduction in MACE in patients with NSTE-ACS and PAD with vorapaxar, compared with placebo, on background clopidogrel and aspirin, but the difference was not statistically significant [ 105 ].

also in 53,322 other papers